Catalyst Pharmaceuticals’ Firdapse, which is used to treat Lambert-Eaton Myasthenic Syndrome, will hit the market with a list price of $375,000 per year, Reuters reports.
The drugmaker announced the price, which excludes discounts and rebates, on Monday. It told investors in New York on Monday that it is looking for the list price to land somewhere between $300,000-$318,750 per year.
According to the report, the drug was originally free through the Food and Drug Administration’s “compassionate use” program, which allows patients suffering from rare diseases to use experimental drugs outside of a trial setting.
Express Scripts says the pricing “takes advantage of vulnerable patients who need this medication.”
To read the full report on Reuters, click here.
